RNAi versus small molecules: different mechanisms and specificities can lead to different outcomes.

  • Fitzgerald K
  • 15

    Readers

    Mendeley users who have this article in their library.
  • 24

    Citations

    Citations of this article.

Abstract

The methodology of RNA interference (RNAi) arrived on the scene of mammalian systems research in 2001. Since that time, there has been widespread use of this technology in both academic and industrial settings. RNAi and small molecules were initially considered as equivalent methods for inhibiting protein activity within cells, but as our understanding of the mechanism of RNAi has improved, it has become apparent that differences in their cellular mechanisms have unexpected consequences. There can be profound differences in the phenotypic outcomes of treatment with RNAi versus small molecules. This review discusses the similarities, as well as the predicted differences between RNAi and small molecule effects on therapeutic paradigms and drug discovery.

Author-supplied keywords

  • Animals
  • Cell Surface
  • Cell Surface: antagonists & inhibitors
  • Drug Design
  • Enzyme Inhibitors
  • Enzyme Inhibitors: pharmacology
  • Humans
  • MicroRNAs
  • MicroRNAs: pharmacology
  • RNA
  • RNA Interference
  • Receptors
  • Small Interfering
  • Small Interfering: pharmacology

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

  • SGR: 24044461406
  • PUI: 41224118
  • PMID: 16159017
  • ISSN: 1367-6733
  • SCOPUS: 2-s2.0-24044461406

Authors

  • Kevin Fitzgerald

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free